Investors Should Know: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma ...

Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

New Delhi: A personalised mRNA vaccine reduced the chances of high-risk melanoma returning or spreading in a Phase 3 trial, US-based pharma companies Moderna and Merck said Wednesday. The vaccine was ...

Moderna’s dramatic ascent this year has been fueled by optimism that its personalized cancer vaccine could reshape oncology and redefine the company beyond its pandemic-era success. That promise may ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer's healthcare headlines today.

The Independent and Yahoo will earn a commission from purchases made via links in this article. Pricing and availability are subject to change. A personalised vaccine given in combination with a drug ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA on Aug. 5, 2026 approved a new mRNA-based flu vaccine. (Melissa Phillip/AP) After months of regulatory questioning, the ...

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 ...

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current ...